Barclays analyst Saket Kalia lowered the firm’s price target on Omada Health (OMDA) to $22 from $29 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the security, design, and vertical-specific software group as part of its 2026 outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health named Top Pick in Healthcare Technology at Morgan Stanley
- Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach
- Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities
- Omada Health initiated with an Outperform at BMO Capital
- Omada Health Reports Strong Growth and Innovation